Caribou Biosciences(CRBU) - 2024 Q3 - Quarterly Results

Exhibit 99.1 1 Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025 -- -- Continuing dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in ...